The Race of mRNA therapy: Evidence from Patent Landscape (preprint)

mRNA therapy is gaining worldwide attention as an emerging therapeutic approach. The widespread use of mRNA vaccines during the COVID-19 outbreak has demonstrated the potential of mRNA therapy. As mRNA-based drugs have expanded and their indications have broadened, more patents for mRNA innovations have emerged. The global patent landscape for mRNA therapy has not yet been analyzed, indicating a research gap in need of filling, from new technology to productization. This study uses social network analysis with the patent quality assessment to investigate the temporal trends, citation relationship, and significant litigation for 16,101 mRNA therapy patents and summarizes the hot topics and potential future directions for this industry. The information obtained in this study not only may be utilized as a tool of knowledge for researchers in a comprehensive and integrated way but can also provide inspiration for efficient production methods for mRNA drugs. This study shows that infectious diseases and cancer are currently the primary applications for mRNA drugs. Emerging patent activity and lawsuits in this field are demonstrating that delivery technology remains one of the key challenges in the field and that drug-targeting research in combination with vector technology will be one of the major directions for the industry going forward. With significant funding, new organizations have developed novel delivery technologies in an attempt to break into the patent thicket established by companies such as Arbutus. The global mRNA therapeutic landscape is undergoing a multifaceted development pattern, and the monopoly of giant companies is being challenged.

Robust Screening of COVID-19 from Chest X-ray via Discriminative Cost-Sensitive Learning (preprint)

This paper addresses the new problem of automated screening of coronavirus disease 2019 (COVID-19) based on chest X-rays, which is urgently demanded toward fast stopping the pandemic. However, robust and accurate screening of COVID-19 from chest X-rays is still a globally recognized challenge because of two bottlenecks: 1) imaging features of COVID-19 share some similarities with other pneumonia on chest X-rays, and 2) the misdiagnosis rate of COVID-19 is very high, and the misdiagnosis cost is expensive. While a few pioneering works have made much progress, they underestimate both crucial bottlenecks. In this paper, we report our solution, discriminative cost-sensitive learning (DCSL), which should be the choice if the clinical needs the assisted screening of COVID-19 from chest X-rays. DCSL combines both advantages from fine-grained classification and cost-sensitive learning. Firstly, DCSL develops a conditional center loss that learns deep discriminative representation. Secondly, DCSL establishes score-level cost-sensitive learning that can adaptively enlarge the cost of misclassifying COVID-19 examples into other classes. DCSL is so flexible that it can apply in any deep neural network. We collected a large-scale multi-class dataset comprised of 2,239 chest X-ray examples: 239 examples from confirmed COVID-19 cases, 1,000 examples with confirmed bacterial or viral pneumonia cases, and 1,000 examples of healthy people. Extensive experiments on the three-class classification show that our algorithm remarkably outperforms state-of-the-art algorithms. It achieves an accuracy of 97.01%, a precision of 97%, a sensitivity of 97.09%, and an F1-score of 96.98%. These results endow our algorithm as an efficient tool for the fast large-scale screening of COVID-19.